TGFB1 and colorectal carcinoma: There are very few therapeutic options; the most promising one is to target CRC-typical pathways such as Wnt/β-catenin, Notch, Hedgehog, NF-κB, Janus kinase/STAT, peroxisome proliferator-activated receptor (PPAR), PI3K/Akt/mTOR and TGF-β pathways (for a detailed review see [231]).